Phase 1 Study Evaluating PHN-012 Antibody-Drug Conjugate Infusion in Adults with Advanced Colon, Lung, and Pancreatic Cancers

What this Trial Is About

Researchers are evaluating PHN-012, a new antibody-drug conjugate, in adults with advanced solid tumors such as colon, lung, and pancreatic cancer. This first-in-human study aims to assess the safety, tolerability, anti-tumor effects, immune response, and how the drug moves through and affects the body. The study is sponsored by Pheon Therapeutics. Participants will receive PHN-012 intravenously. The study includes Phase 1a and Phase 1b periods. Researchers will monitor for dose-limiting toxicities, adverse events, and treatment interruptions over 12 to 24 months. The trial will measure overall response rates and detailed pharmacokinetics during these phases. During the trial, participants will undergo regular evaluations including tumor assessments, safety monitoring, and blood tests to analyze drug levels and immune reactions. The study will track participants for up to 24 months to understand the best overall response, disease control, survival, and side effects. Participation involves multiple visits for treatment and follow-up assessments throughout the study duration.

A Study of PHN-012 in Patients With Advanced Solid Tumors